Scientific Name: Cangrelor
Brand Name: Kengreal, Kengrexal
Company Owner: Not Available
Mechanism Of Action Cangrelor is a selective, reversible, P2Y12 platelet receptor antagonist which inhibits ADP platelet aggregation. ADP is typically released by damaged blood vessels, red blood cells, and/or platelets due to agonists stimulating platelet activity. ADP binds to P2Y12 to stimulate and complete platelet aggregation by inhibiting adenylyl cyclase by a Gi protein, thus potentiating dense granule secretion and increasing coagulation activity. Cangrelor acts on the same target as oral irreversible inhibitors clopidogrel and ticlopidine and has a similar mechanism of action, but is reversible and provides a fast onset and offset of action.
Description of the Drug: Cangrelor is a P2Y12 platelet receptor antagonist used during percutaneous coronary intervention to reduce the risk for periprocedural myocardial infarction (MI) , repeat coronary revascularization, and stent thrombosis (ST) .
Protein Data Bank: Not Available
Source: DrugBank Online – Retrieved 2023-01-23 from